The JACS prospective cohort study of newly diagnosed women with breast cancer investigating joint and muscle pain, aches, and stiffness: Pain and quality of life after primary surgery and before adjuvant treatment

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Fenlon, Deborah ^a   Powers, Cassandra ^a   Simmonds, Peter ^b   Clough, Joanne ^c   Addington Hall, Julia ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aromatase inhibitors; Arthralgia; Breast cancer; Cohort study

Indexed keywords

ANALGESIC AGENT;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; BRIEF PAIN INVENTORY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER SURGERY; COHORT ANALYSIS; DEPRESSION; DISEASE SEVERITY; DRUG USE; FEMALE; HEALTH IMPACT ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MUSCULOSKELETAL STIFFNESS; PATIENT PARTICIPATION; POSTMENOPAUSE; PREVALENCE; PRIMARY TUMOR; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36; UNITED KINGDOM; BREAST NEOPLASMS; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MUSCULOSKELETAL PAIN; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS;

EID: 84902928753     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-467     Document Type: Article

References (41)

1. Breast cancer incidence statistics. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/incidence/.
2. Key Facts Breast Cancer. http://publications.cancerresearchuk.org/downloads/Product/CS_KF_BREAST.pdf.
3. Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Nomura Y, Sakai K, Sugimachi K, Tominaga T, Uchino J, Yoshida Y, Van De Velde AO, Van Dongen JA, Vermorken JB, Giokas G, Lissaios B, Harvey VJ, Holdaway TM, Kay RG, Mason BH, Coates AS, Forbes John F, Focan C, Lobelle JP, Peek U, Oates GD, Powell J, Durand MC, Mauriac L, Bartholomeus S, Piccart-Gebhart M, et al. Tamoxifen for early breast cancer: an overview of the randomised trials. Early breast cancer Trialists' collaborative group. Lancet 1998, 351(9114):1451-1467.
4. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007, 25(25):3877-3883.
5. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010, 28(3):509-518.
6. Boonstra A, van Zadelhoff J, Timmer-Bonte A, Ottevanger PB, Beurskens CH, van Laarhoven HW. Arthralgia during aromatase inhibitor treatment in early breast cancer patients: prevalence, impact, and recognition by healthcare providers. Cancer Nurs 2012, 36(1):52-9.
7. Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 2010, 120(1):127-134.
8. Dizdar O, Ozcakar L, Malas FU, Harputluoglu H, Bulut N, Aksoy S, Ozisik Y, Altundag K. Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol 2009, 27(30):4955-4960.
9. Honda J, Kanematsu M, Nakagawa M, Takahashi M, Nagao T, Tangoku A, Sasa M. Joint symptoms, aromatase inhibitor-related adverse reactions, are indirectly associated with decreased serum estradiol. Int J Surg Oncol 2011, 2011:951260.
10. Lintermans A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R, Dieudonne AS, Leunen K, Morales L, Verschueren K, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann Oncol 2011, 22(8):1763-1769.
11. Dent SF, Gaspo R, Kissner M, Pritchard KI. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat 2011, 126(2):295-310.
12. Fenlon D, Addington-Hall JM, O'Callaghan AC, Clough J, Nicholls P, Simmonds P. A survey of joint and muscle aches, pain, and stiffness comparing women with and without breast cancer. J Pain Symptom Manag 2013, 46(4):523-35.
13. Castel LD, Hartmann KE, Mayer IA, Saville BR, Alvarez J, Boomershine CS, Abramson VG, Chakravarthy AB, Friedman DL, Cella DF. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Cancer 2013, 119(13):2375-2382.
14. Robidoux A, Rich E, Bureau NJ, Mader S, Laperriere D, Bail M, Tremblay N, Patenaude M, Turgeon J. A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy. Curr Oncol (Toronto, Ont) 2011, 18(6):285-294.
15. Henry NL, Pchejetski D, A'Hern R, Nguyen AT, Charles P, Waxman J, Li L, Storniolo AM, Hayes DF, Flockhart DA, Stearns V, Stebbing J. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. Br J Cancer 2010, 103(3):291-296.
16. Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 2005, 52(9):2594-2598.
17. Coleman RE, Bolten WW, Lansdown M, Dale S, Jackisch C, Merkel D, Maass N, Hadji P. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 2008, 34(3):275-282.
18. Geisler J, Lonning PE. Impact of aromatase inhibitors on bone health in breast cancer patients. J Steroid Biochem Mol Biol 2010, 118(4-5):294-299.
19. Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, DeMichele A. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 2009, 115(16):3631-3639.
20. Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol 2012, 13(4):420-432.
21. Shi Q, Giordano SH, Lu H, Saleeba AK, Malveaux D, Cleeland CS. Anastrozole-associated joint pain and other symptoms in patients with breast cancer. J Pain 2013, 14(3):290-296.
22. Saibil S, Fitzgerald B, Freedman OC, Amir E, Napolskikh J, Salvo N, Dranitsaris G, Clemons M. Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr Oncol (Toronto, Ont) 2010, 17(4):42-47.
23. Thornton LM, Carson WE, Shapiro CL, Farrar WB, Andersen BL. Delayed emotional recovery after taxane-based chemotherapy. Cancer 2008, 113(3):638-647.
24. Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006, 24(34):5381-5387.
25. Siminoff LA, Fetting JH, Abeloff MD. Doctor-patient communication about breast cancer adjuvant therapy. J Clin Oncol 1989, 7(9):1192-1200.
26. Morales L, Pans S, Paridaens R, Westhovens R, Timmerman D, Verhaeghe J, Wildiers H, Leunen K, Amant F, Berteloot P, Smeets A, Van Limbergen E, Weltens C, Van den Bogaert W, De Smet L, Vergote I, Christiaens M, Neven P. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 2007, 104(1):87-91.
27. Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes D, Storniolo AM, Clauw D. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 2008, 111(2):365-372.
28. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 2012, 30(9):936-942.
29. Carpenter JS, Andrykowski MA. Menopausal symptoms in breast cancer survivors. Oncol Nurs Forum 1999, 26(8):1311-1317.
30. Breast Cancer Care Your follow-up after breast cancer: what's next? Factsheet 2011, London: Breast Cancer Care, Breast Cancer Care.
31. Helzlsouer KJ, Gallicchio L, MacDonald R, Wood B, Rushovich E. A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms. Breast Cancer Res Treat 2012, 131(1):277-285.
32. Kuorinka I, Jonsson B, Kilbom A, Vinterberg H, Biering-Sorensen F, Andersson G, Jorgensen K. Standardised Nordic questionnaires for the analysis of musculoskeletal symptoms. Appl Ergon 1987, 18(3):233-237.
33. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994, 330(9):592-596.
34. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 1997, 15(3):974-986.
35. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 1999, 55(2):189-199.
36. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30(6):473-483.
37. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 2007, 18(6):800-804.
38. Joint Formulary Committee British National Formulary No. 63. vol. 63, March 2012 edn 2012, London: BMJ Group and Pharmaceutical Press, Joint Formulary Committee.
39. Burk R. Aromatase inhibitor-induced joint pain: melatonin's role. Med Hypotheses 2008, 71(6):862-867.
40. Napoli N, Vattikuti S, Ma C, Rastelli A, Rayani A, Donepudi R, Asadfard M, Yarramaneni J, Ellis M, Armamento-Villareal R. High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer. Breast J 2010, 16(6):609-616.
41. Janni W, Hepp P. Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev 2010, 36(3):249-261.